AI-derived histology biomarker stratifies first-line chemotherapy outcomes in advanced pancreatic cancer
The CHAI computational-histology platform generated a locked H&E-based biomarker intended to distinguish advanced pancreatic ductal adenocarcinoma patients with differential outcomes on fluoropyrimidine-based versus gemcitabine-based chemotherapy. In an independent validation cohort of 299 patients from the prospectively collected COMPASS and Know Your Tumor cohorts, the 173 patients classified F-pref had longer time to next treatment or death (8.6 vs 7.5 months, P=.035) and overall survival (14.4 vs 11.7 months, P=.003) on F- versus G-based therapy. Among 126 G-pref patients, G-based therapy was associated with longer time to next treatment or death (9.6 vs 7.2 months, P=.038), but not significantly different overall survival.
Technology: Computational Histology Artificial Intelligence (CHAI) platform
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent validation cohort of 299 patients from the prospectively collected COMPASS and Know Your Tumor cohorts, the 173 patients classified F-pref had longer time to next treatment or death (8.6 vs 7.5 months, P=.035) and overall survival (14.4 vs 11.7 months, P=.003) on F- versus G-based therapy. The locked biomarker was applied to assembled data from prospectively collected cohorts; prospective validation of treatment selection is still needed.
- Still unknown: Validation used 299 patients in two prospectively collected but nonrandomized cohorts; treatment assignment was not randomized, and the authors also used propensity weighting and target-trial emulation. The primary endpoint was time to next treatment or death, not progression-free survival. In the biomarker’s G-pref subgroup, the OS comparison was not significant. The authors call for further prospective validation before clinical adoption. An earlier CHAI study concerned adjuvant gemcitabine outcomes in resected disease; this entry is limited to the distinct locked first-line fluoropyrimidine-versus-gemcitabine biomarker and external-cohort results in advanced disease.
- AI role: Deep-learning models segmented H&E biopsy slides and quantified more than 30,000 histomorphologic features. Using the development cohort, the investigators statistically selected and weighted features into a treatment-preference biomarker and locked its threshold before applying it to an independent validation cohort. The platform supplied the image-derived feature measurements used in the biomarker; this is a biomarker-development and validation result, not autonomous treatment assignment.
Evidence sources: https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-02199
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.